Whalesbook
The Indian pharmaceutical giant Sun Pharmaceutical Industries announced on Friday it has secured regulatory approval to produce and market a generic version of Novo Nordisk's blockbuster weight-loss drug Wegovy within India. This significant development marks Sun Pharma's entry into a rapidly expanding and lucrative segment of the pharmaceutical market. The company intends to launch generic semaglutide, the active ingredient in Wegovy and Ozempic, under the brand name Noveltreat. This strategic move is timed to coincide with the semaglutide patent's expiration in March 2026. The approval follows closely on the heels of a similar nod for Dr. Reddy's Laboratories, which announced earlier this week its approval to manufacture and sell a generic version of Ozempic, a drug that shares the same active ingredient.
Race for the Lucrative Weight-Loss Market
The approval for Sun Pharma's generic semaglutide underscores the intense competition among Indian pharmaceutical firms vying for market share in the burgeoning weight-loss drug sector. With Novo Nordisk's semaglutide patents set to expire, numerous Indian generic manufacturers are accelerating their efforts to capitalize on this opportunity. Sun Pharma's regulatory clearance places it among the frontrunners, alongside Dr. Reddy's Laboratories, which is also preparing to launch its generic version of Ozempic. The combined market for these GLP-1 therapies is projected to unlock substantial revenue potential for generic players. Analysts estimate the impending patent expiry could generate over ₹50,000 crore for generic drug manufacturers globally within 12-15 months. In India specifically, the launch of generic semaglutide is expected to boost the overall Indian Pharmaceutical Market (IPM) growth by 0.5-1% in the first quarter of FY27. The anticipated price reduction, potentially 30-50% lower than current levels, with further cuts up to 70-75% over time, is expected to significantly broaden access to these therapies for diabetic patients.
Competitive Positioning and Market Dynamics
Sun Pharmaceutical Industries, a large-cap entity with a market capitalization of approximately ₹392,147 crore, currently trades with a P/E ratio around 37-40x. Its P/E ratio is slightly above the industry average, suggesting a premium valuation. In contrast, Dr. Reddy's Laboratories, with a market capitalization of around ₹101,616 crore, trades at a P/E ratio of approximately 17-18x, indicating a more value-oriented valuation. Both companies are positioning themselves aggressively. Dr. Reddy's has a targeted launch for its semaglutide in India by March 21. The broader Indian generic drugs market is valued at $24.53 billion and is projected to grow at a CAGR of 6.97%. The global GLP-1 market is forecast to exceed $157.5 billion by 2035. While Sun Pharma has recently clarified that reports of a potential $10 billion acquisition of US-based Organon were speculative, its strategic focus remains on expanding its product portfolio. The company's Baska manufacturing facility received an Official Action Indicated (OAI) status from the US FDA following an inspection, though Sun Pharma stated it would continue manufacturing approved products from the site. Novo Nordisk, the originator of Wegovy and Ozempic, has a trailing P/E ratio around 16-17x. The company has faced supply constraints, which creates an opening for generic manufacturers.
Outlook and Industry Trends
The entry of generic semaglutide is expected to significantly alter the market dynamics, driving wider adoption of GLP-1 therapies. Analysts caution that success will depend on timely regulatory approvals and competitive strategies. Beyond India, companies like Sun Pharma and Dr. Reddy's are also looking at regulated markets such as Canada and Brazil, where semaglutide patents are also set to expire. The Indian pharmaceutical sector continues to demonstrate strong fundamentals, with profitability margins rebounding. The industry's robust manufacturing infrastructure and skilled workforce position India as a key global supplier of generic medicines, catering to a significant portion of demand in regions like Africa and the United States. While Sun Pharma faces some near-term concerns regarding growth beyond generic Revlimid settlements and potential margin contraction, its Indian revenue has shown strong YoY growth. Dr. Reddy's, despite strong Q3 results, sees divided analyst sentiment, with some expressing concerns about future earnings pressure from increased R&D spending.